Skip to main content
  • Poster presentation
  • Open access
  • Published:

Treatment of calcinosis with biphosphonates in juvenile dermatomyositis

Juvenile dermatomyositis (JDM) is a multisystem disease that is characterized by nonsuppurative inflammation of striated muscle and skin. Dystrophic calcification occurs in up to 40% of children We present our treatment approach in four JDM patients with calcinosis. Four female patients (median age 8.5 years, range 6–14) had been diagnosed as JDM in our center. Two of them presented with severe disease and calsifications in the the other two, despite successful treatment of myopathy with steroids, methotrexate and cycylosporin, calcinosis had developed within 10 months (ranging 4–16 months) of initial diagnosis. Two of the patients who had generalized calcinosis and severe osteoporosis were given iv pamidronate and the other two were treated with oral alendronate in addition to oral diltiazem, calcium and vitamin D supplementation. After 7 months of treatment (ranging 5–14 months) clinical and radiological examination revealed dramatic regression of the calcinosis. Bone mass improved as determined by bone absorptiometry. Biphosphonates oral or iv according to the severity of the disease could be a useful therapy in patients with JDM and calcinosis in addition to aggressive therapy of inflammation.

Author information

Authors and Affiliations


Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Bilginer, Y., Topaloglu, R. & Gonc, N. Treatment of calcinosis with biphosphonates in juvenile dermatomyositis. Pediatr Rheumatol 6 (Suppl 1), P220 (2008).

Download citation

  • Published:

  • DOI: